Skip to main content

NCT03619512 - Genomic and Proteomic Study of Richter Syndrome (CGPSR)

Official Title
Genomic and Proteomic Study of Richter Syndrome
Brief Title
Genomic and Proteomic Study of Richter Syndrome (CGPSR)
Protocol ID
NCT03619512
Lead Sponsor
Central Hospital, Nancy, France
Brief Summary
Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to chemorefractoriness. This study aims at understanding the biological determinants of chemotherapy resistance in Richter Syndrome.
Detailed Description
With the help of the French National Research Group on CLL (FILO / French Innovative Leukemia Organization), the investigators are currently gathering fresh frozen cell pellets at CLL stage, and lymph node biopsies at Richter stage. The investigators also gathered lymph node biopsies from DLBCL, as a reference group. The investigators will perform genomic and proteomic comparative studies between CLL and Richter, as well as between Richter and primitive DLBCL, to understand the biological determinants of clonal evolution and chemorefractoriness of Richter Syndrom.
Study Period
-
Enrollment Count
170 participants
Eligibility Criteria
Inclusion Criteria: - Diagnosis of a Diffuse Large B-Cell Lymphoma arising in the context of a Chronic Lymphocytic Leukemia (group 1) or diagnosis of a primitive Diffuse Large B-Cell Lymphoma (group 2), or diagnosis of a Diffuse Large B-Cell Lymphoma arising in a context of small cells lymphoma, excluding CLL (group 3), or benefit from a diagnostic lymph node biopsy that did not reveal any tumor involvment (primitive or metastatic) (group 4). - Patients must benefit from a lymph node biopsy at diagnosis. - Patients must be followed by a FILO (French Innovative Leukemia Organization) member - Histology of Diffuse Large B-Cell Lymphoma or Hodgkin histology. - Suitable clinical data available. - Samples must meet the following requirement :RIN (RNA Integrity Number) > 5 et DIN (DNA Integrity Number) > 6.5. Exclusion Criteria: • Samples that do not meet the inclusion criteria (insufficient clinical data, analysis impossible due to insufficient sample quality).
Filters
Richter Syndrome
UNKNOWN
CHILD
ADULT
OLDER_ADULT